BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August

Day

• 1
• 2
• 3
• 4
• 7
• 8
• 9
• 10
• 11
• 13
• 14
• 15
• 16
• 17
• 18
• 21
• 22
• 23
• 24
• 25
• 28
• 29
• 30

• Press Releases

  RECORDATI: 2025-2027 THREE-YEAR PLAN APPROVED FY 2027 TARGETS OF REVENUE BETWEEN € 3,000 AND € 3,200 MILLION; EBITDA(1) BETWEEN € 1,140 AND € 1,225 MILLION; ADJUSTED NET INCOME(2) BETWEEN € 770 AND € 820 MILLION

  April 29, 2025

   · 

  6 min read
• Press Releases

  Late-Breaking Research from SK Life Science Labs at AACR Annual Meeting Shows p300-Selective Degraders are Potent Growth Inhibitors in Models of Aggressive Prostate Cancers and Solid Tumors

  April 29, 2025

   · 

  4 min read
• Press Releases

  BriaCell Therapeutics Announces Closing of $13.8 million Public Offering

  April 29, 2025

   · 

  4 min read
• Press Releases

  Privo Technologies Expands CLN-004 Clinical Trial Across Leading U.S. Cancer Centers

  April 29, 2025

   · 

  2 min read
• Press Releases

  Voyager Next-Generation CNS Capsids Featured at ASGCT 28th Annual Meeting

  April 29, 2025

   · 

  8 min read
• Press Releases

  Lynozyfic™ (linvoseltamab) Approved in the European Union for the Treatment of Relapsed/Refractory Multiple Myeloma

  April 29, 2025

   · 

  14 min read
• Press Releases

  Auron Presents Preclinical Data Highlighting the Activity of AUTX-703 in Prostate Cancer at 2025 AACR Annual Meeting

  April 29, 2025

   · 

  2 min read
• Press Releases

  ElevateBio Announces Transition of David Hallal to Executive Chairman of the Board of Directors

  April 29, 2025

   · 

  2 min read
• Press Releases

  Monte Rosa Therapeutics Presents Preclinical Data at American Association for Cancer Research (AACR) Annual Meeting 2025 on the Potential of its CDK2-directed Molecular Glue Degrader to Treat HR-positive/HER2-negative Breast Cancer

  April 29, 2025

   · 

  8 min read
• Press Releases

  Krystal Biotech Announces European Commission Approval of VYJUVEK® for the Treatment of Dystrophic Epidermolysis Bullosa

  April 29, 2025

   · 

  5 min read